Rousta Sepideh T
aDivision of Pediatric Ophthalmology, Robert Wood Johnson Medical School, New Brunswick, New Jersey bWills Eye Hospital, Philadelphia, Pennsylvania, USA.
Curr Opin Ophthalmol. 2017 Sep;28(5):449-453. doi: 10.1097/ICU.0000000000000399.
This article highlights the importance of recognizing blepharokeratoconjunctivitis (BKC) in children and reviews the clinical characteristics and current therapeutic modalities.
The mainstay of BKC treatment remains controlling the meibomian gland inflammation and treating cobormid conditions. BKC can occur in the setting of ocular rosacea and Demodex infestation. Small studies have shown treatment benefits of topical cyclosporine A as well as oral azithromycin in pediatric BKC.
BKC is a cause for visual loss in children, and therefore pediatric ophthalmologists should be more vigilant about early diagnosis and long-term treatment. There is a lack of randomized controlled trials on this topic and no standardized outcome measures. Better ways to measure the clinical outcome of various treatment modalities need to be developed.
本文强调了认识儿童睑缘角结膜炎（BKC）的重要性，并回顾了其临床特征和当前的治疗方式。
BKC治疗的主要方法仍然是控制睑板腺炎症和治疗合并症。BKC可发生于眼部酒渣鼻和蠕形螨感染的情况下。小型研究表明，局部用环孢素A以及口服阿奇霉素对儿童BKC有治疗益处。
BKC是儿童视力丧失的一个原因，因此小儿眼科医生应更加警惕早期诊断和长期治疗。关于这一主题缺乏随机对照试验，也没有标准化的结局指标。需要开发更好的方法来衡量各种治疗方式的临床结局。
